ClinicalTrials HQ

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Recruiting · NCT06450041 · Registry updated 2026-07-20
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialNeoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumorRecruitingPhase 22026-07-20NCT06450041

4 results · Page 1 of 1

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Boston Children's Hospital, Dana-Farber Cancer Institute.BostonUnited States1
C.S Mott Children's HospitalAnn ArborUnited States7
Children's Hospital ColoradoAuroraUnited States312
Children's Hospital Los AngelesLos AngelesUnited States6
Children's Hospital of PhiladelphiaPhiladelphiaUnited States6
Cincinnati Children's Hospital Medical CenterCincinnatiUnited States21
Comer Children's Hospital, University of ChicagoChicagoUnited States1
Cook Children's Medical CenterFort WorthUnited States111
Nationwide Children's HospitalColumbusUnited States309
Seattle Children's HospitalSeattleUnited States281
St. Jude Children's Research HospitalMemphisUnited States194
UCSF Benioff Children's HospitalSan FranciscoUnited States5
University of Texas SouthwesternDallasUnited States16